Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saizen in Children With Hypochondroplasia
NCT01111019Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Mar 2006
- Primary completion
- Jan 2017
- Modality
- Hormone, rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of somatropin in hypochondroplasia (HCH), sponsored by Merck KGaA. Primary endpoints: Change From Baseline in Height-Standard Deviation Score at 3 years and Height-Standard Deviation Score at 4 years. Started Mar 2006; status: completed.
02
Drugs
somatropin
03
Conditions
hypochondroplasia (HCH)
Beyond the preview
Go deeper on NCT01111019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01111019.